{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:03Z","timestamp":1747181163323,"version":"3.40.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:p>Benign prostatic hypertrophy (BPH) is associated with autonomic dysfunction and sympathetic nervous system mediated by the alpha receptor. However, limited data exist regarding the effects of the beta-blocker (BB) carvedilol on arrhythmia and urologic outcomes in BPH patients. Our database of patients diagnosed with BPH from 2015 to 2020 was used to obtain echocardiography and electrocardiogram data. Inclusion criteria were BPH patients taking BBs. International Prostate Symptom Score questionnaire were used to evaluate the urinary symptoms and quality of life. Among 448 patients with BPH (69.2\u2009\u00b1\u200910.9 years) taking BBs, 219 patients took carvedilol (48.9%) and 229 patients took a non-carvedilol BB (51.1%; bisoprolol, 184 patients, 80% or nebivolol, 45 patients, 20%). Difference in the baseline characteristics was not observed. During the median 36-month follow-up, a lower incidence of arrhythmic events (<jats:italic toggle=\"yes\">P<\/jats:italic> = .029), total urologic events (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001), and less use of additive alpha-blocker was observed in the carvedilol group (<jats:italic toggle=\"yes\">P<\/jats:italic> = .022). In multivariate analysis, less carvedilol use (<jats:italic toggle=\"yes\">P<\/jats:italic> = .019), heart failure (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001), stroke (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001), and cardiomyopathy (<jats:italic toggle=\"yes\">P<\/jats:italic> = .046) were independent risk factors for arrhythmic events. In addition, less carvedilol use (<jats:italic toggle=\"yes\">P<\/jats:italic> = .009) and older age (<jats:italic toggle=\"yes\">P<\/jats:italic> = .005) were independent risk factors for urologic events based on BB type at the median 36-month follow-up. The use of carvedilol was associated with less arrhythmic events in BPH patients with palpitation and decreased the incidence of urologic events in BPH compared with the use of non-carvedilol BBs in long-term follow-up.<\/jats:p>","DOI":"10.1097\/md.0000000000035008","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:06:51Z","timestamp":1694182011000},"page":"e35008","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effects of the beta-blocker carvedilol on arrhythmia and long-term clinical outcomes in benign prostate hypertrophy patients"],"prefix":"10.1097","volume":"102","author":[{"given":"Soo Jin","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Su","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pil Moon","family":"Kang","sequence":"additional","affiliation":[{"name":"Kang Pil Urology Clinic, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Ho","family":"Heo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taek Sang","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-2422","authenticated-orcid":false,"given":"Sung Il","family":"Im","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0022-5347(17)34983-2","article-title":"Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy.","volume":"151","author":"Carr","year":"1994","journal-title":"J Urol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.kjms.2012.08.003","article-title":"The effect of carvedilol on serum and tissue oxidative stress parameters in partial ureteral obstruction induced rat model.","volume":"29","author":"Yasar","year":"2013","journal-title":"Kaohsiung J Med Sci"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2009.12.010","article-title":"Progression of paroxysmal to persistent atrial fibrillation factors promoting the HATCH score.","volume":"55","author":"Jahangir","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-13-1272","article-title":"Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation.","volume":"78","author":"Senoo","year":"2014","journal-title":"Circ J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s002400050086","article-title":"Obstructive nephropathy: an update of the experimental research.","volume":"27","author":"Wen","year":"1999","journal-title":"Urol Res"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/archinte.166.5.554","article-title":"Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the coronary event and periodontal disease (CORODONT) study.","volume":"166","author":"Spahr","year":"2006","journal-title":"Arch Intern Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jelectrocard.2009.12.002","article-title":"Effect of periodontitis on susceptibility to atrial fibrillation in an animal model.","volume":"43","author":"Yu","year":"2010","journal-title":"J Electrocardiol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11884-010-0067-2","article-title":"Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors.","volume":"5","author":"Parsons","year":"2010","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0970-1591.126900","article-title":"Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction.","volume":"30","author":"Patel","year":"2014","journal-title":"Indian J Urol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.hrthm.2008.08.011","article-title":"Atrial fibrillation progression and management: a 5-year prospective follow-up study.","volume":"5","author":"Pappone","year":"2008","journal-title":"Heart Rhythm"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification.","volume":"7","author":"Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/clc.23063","article-title":"Increased risk of atrial fibrillation in patients with benign prostatic hyperplasia: a population-based cohort study.","volume":"41","author":"Hu","year":"2018","journal-title":"Clin Cardiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jphs.2017.03.003","article-title":"Involvement of alpha- and beta-adrenoceptors in the automaticity of the isolated guinea pig pulmonary vein myocardium.","volume":"133","author":"Irie","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0021-9150(92)90133-2","article-title":"Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper.","volume":"97","author":"Yue","year":"1992","journal-title":"Atherosclerosis"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0014-2999(92)90130-V","article-title":"Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils.","volume":"214","author":"Yue","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0022-3565(25)10363-7","article-title":"Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger.","volume":"263","author":"Yue","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mehy.2009.12.025","article-title":"Practical prevention of cardiac remodeling and atrial fibrillation with full-spectrum antioxidant therapy and ancillary strategies.","volume":"75","author":"McCarty","year":"2010","journal-title":"Med Hypotheses"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mehy.2012.10.009","article-title":"Atrial remodeling: new pathophysiological mechanism of atrial fibrillation.","volume":"80","author":"Xu","year":"2013","journal-title":"Med Hypotheses"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejphar.2013.07.043","article-title":"Proton pump inhibitors as also inhibitors of atrial fibrillation.","volume":"718","author":"Lin","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jacc.2007.06.054","article-title":"Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data.","volume":"50","author":"Issac","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.molmed.2011.05.007","article-title":"Inflammatory pathways underlying atrial fibrillation.","volume":"17","author":"Friedrichs","year":"2011","journal-title":"Trends Mol Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ijcard.2009.03.099","article-title":"An insidious risk factor for cardiovascular disease: benign prostatic hyperplasia.","volume":"144","author":"Karatas","year":"2010","journal-title":"Int J Cardiol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.urology.2013.03.087","article-title":"Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.","volume":"82","author":"Lewandowski","year":"2013","journal-title":"Urology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00210-015-1136-z","article-title":"Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction.","volume":"388","author":"Gillespie","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:28:07Z","timestamp":1746325687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":25,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035008","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}